Pharmacodynamic model of rocuronium in patients with muscle relaxation: comparison of electromyography-based and acceleromyography-based neuromuscular monitoring

Pharmacodynamic model of rocuronium in patients with muscle relaxation: comparison of electromyography-based and acceleromyography-based neuromuscular monitoring - Pharmacodynamic modeling of rocuronium in patients with general anesthesia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044298

Enrollment

Registered

2021-05-23

Start date

2021-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for surgery under general anesthesia that requires neuromuscular blockade only for intubation

Interventions

Use of electromyography-based and acceleromyography-based neuromuscular monitors, simultaneously during general anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient scheduled for elective surgery that requires neuromuscular blockade only for anesthesia induction

Exclusion criteria

Exclusion criteria: Patients with severe hepatic, renal, or cardiovascular disease, neuromuscular disease, a history of rocuronium allergy, body mass index greater than 35 kg/m2

Design outcomes

Primary

Measure	Time frame
Pharmacodynamic model of rocuronium in patients with deep muscular blockade using electromyography-based and acceleromyography-based neuromuscular monitoring	—

Secondary

Measure	Time frame
(1) Difference in rocuronium pharmacodynamic models between electromyography-based and acceleromyography-based neuromuscular monitoring (2) Pharmacodynamic parameters of rocuronium (3) Relationship between effect-site concentration and neuromuscular effect (4) Difference in effect-site concentration for between the concentration of rocuronium effective site for electromyography-based and acceleromyography-based neuromuscular monitoring	—

Measure

Time frame

(1) Difference in rocuronium pharmacodynamic models between electromyography-based and acceleromyography-based neuromuscular monitoring (2) Pharmacodynamic parameters of rocuronium (3) Relationship between effect-site concentration and neuromuscular effect (4) Difference in effect-site concentration for between the concentration of rocuronium effective site for electromyography-based and acceleromyography-based neuromuscular monitoring

—

Countries

Japan

Contacts

Public ContactKenichi Masui

Showa University School of Medicine Department of Anesthesiology

kenichi@masuinet.com03-3784-8575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026